

Thembisa versions

This document summarizes the history of the development of the Thembisa model, and explains the key differences between the different versions of the Thembisa model. Users of Thembisa model outputs should rely on the most recent version of the model as far as possible, but may find it useful to refer to this document when trying to understand differences in results between model versions.

Thembisa version 1.0 (February 2014)

This was the first version of the Thembisa model to be published. Although a working paper was published that described the model and presented results [1], the model itself was not published because the demographic assumptions were preliminary and required further work.

Thembisa version 2.4 (May 2016)

Thembisa version 2.4 is an adaptation of Thembisa version 1.0, created for the purpose of an assessment of long-term prospects for HIV control in South Africa (identifying the model variables most critical to future reductions in HIV incidence and assessing South Africa's potential to achieve the 90-90-90 targets) [2]. The following are the most important structural changes relative to version 1.0:

- The modelling of HCT uptake was revised, as described previously [3]. Very briefly, version 2.4 allowed for retesting of individuals who had previously tested positive, assumed a different age pattern of HIV testing, calculated rates of HIV testing from reported numbers of HIV tests, and assumed the same rates of HIV testing in HIV-negative and undiagnosed HIV-positive individuals (after controlling for other factors).
- Version 1.0 did not explicitly model ART interruptions/discontinuations. Version 2.4 makes some allowance for ART interruptions: individuals are still classified according to the time since they *first* started ART, but in each duration category, a proportion of ART patients is assumed to be temporarily interrupting ART. People who temporarily interrupt ART are assumed to have the same infectiousness as untreated individuals, and their CD4 count is assumed to be the same as it was prior to ART initiation.
- A number of parameters have been added into version 2.4 in order to model the uncertainty in the future course of the epidemic. The first of these is the effect of viral suppression on HIV transmission: whereas version 1.0 contained a single assumption about the relative infectiousness of individuals on ART (compared to individuals not receiving ART), version 2.4 includes a number of parameters (the rate of virological suppression in each year, average viral loads prior to ART initiation, and the increase in HIV infectiousness per unit increase in the log viral load).
- New parameters were also introduced into version 2.4 to represent the effect of timing of ART initiation in pregnancy on the probability of mother-to-child transmission. In version 1.0, it was assumed that mothers starting ART in pregnancy all had the same probability of mother-to-child transmission, but the new model allows for changes over time in the mean duration of ART exposure prior to delivery.

- The ratio of female HIV disease progression rates to those in males was changed from 1.0 in version 1.0 of Thembisa to 0.9 in version 2.4.
- Version 2.4 allows for changes over time in the fraction of male births that are circumcised neonatally (version 1.0 assumed this fraction remained constant).

Various parameter values were updated in version 2.4 to reflect updated information on the rollout of HIV prevention and treatment services, and the model was recalibrated to HIV prevalence data and HCT data. However, the demographic parameters have not yet been updated, and the model has therefore not been placed on the Thembisa website.

Thembisa version 2.5 (August 2016)

Thembisa version 2.5 is an adaptation of Thembisa version 2.4. This is the first version of the model to include province-specific parameters (i.e. the model can be run for the country as a whole and for each of the provinces) [4, 5]. The key structural changes to the model are as follows:

- Version 2.5 allows for the rollout of PrEP to commercial sex workers, from mid-2016.
- Version 2.5 includes allowance for PCR testing in HIV-exposed infants at birth (version 2.4 only allowed for PCR testing at 6 weeks of age). However, due to lack of data on the uptake of birth testing and early indications that the uptake of birth testing might compromise the uptake of testing at 6 weeks, the default assumption remains that rates of PCR uptake at birth are zero.
- Version 2.5 allows for the extension of ART eligibility to all children aged 1-4, from mid-2012.

Thembisa version 3.2 (September 2017)

Thembisa version 3.2 is an update to Thembisa version 2.5. Key differences between the two models are as follows:

- Version 3.2 has been extended to include men who have sex with men (MSM).
- Mother-to-child transmission parameters have been revised in version 3.2, with the result that annual numbers of new infections in children have been reduced.
- Changes have been made to the assumed patterns of medical male circumcision uptake, with uptake being highest in adolescent males, independent of sexual risk behaviour.
- Version 3.2 allows for birth testing (in addition to 8-10 week testing) of children born to HIV-positive mothers.
- Version 3.2 allows for changes in rates of CD4 decline over time, potentially as a result of changes in HIV virulence [6].

Thembisa version 4.1 (August 2018)

Thembisa version 4.1 is an update to Thembisa version 3.2. Key differences between the two models are as follows:

- Version 4.1 classifies HIV-positive children according to whether they have been diagnosed HIV-positive, and the model of ART initiation in children has been revised so that children can only start ART if they have been diagnosed.

- The model of PrEP initiation has been revised, to allow for PrEP initiation in MSM as well as to allow for age, sex and risk group differences in PrEP uptake. Assumptions about PrEP efficacy have also been revised upward.
- Assumptions about rates of treatment interruption and resumption of ART after an interruption have been revised substantially, based on recent South African studies.
- The model of viral suppression after ART initiation has been updated to allow for changes in rates of viral suppression over time, and to allow for anticipated increases in viral suppression following the introduction of dolutegravir.
- The output files for version 4.1 are generated using the C++ version of the Thembisa model (previously the output files were generated using the Excel version of the model). This means that the published outputs include 95% confidence intervals.

Thembisa version 4.2 (June 2019)

This is an update to Thembisa version 4.1. The most significant changes are:

- Thembisa 4.2 is calibrated to recorded death data in children, and this has led to substantial changes in the paediatric HIV estimates (especially AIDS deaths, HIV prevalence and ART coverage in children).
- Assumptions about levels of viral suppression have changed substantially, based on more recent viral suppression data. The new model reports levels of viral suppression at two thresholds: <400 RNA copies per ml (the threshold used previously, which is consistent with most South African reporting) and <1000 RNA copies per ml (the threshold recommended for UNAIDS indicator reporting).
- The modelling of medical male circumcision has been modified, with Thembisa 4.2 assuming that the demand for traditional male circumcision and the demand for medical male circumcision are mutually exclusive.
- More detail is included in the output files, with greater age stratification of estimates.

Thembisa version 4.3 (June 2020)

This is an update to Thembisa version 4.2. The most significant changes are:

- Based on recent data from the Western Cape, the model assumes substantially higher fertility rates in women on ART than had been assumed previously, which has led to higher estimated numbers of births to HIV-positive women.
- The new model also allows for ART interruption in women who were on ART prior to conception, which leads to higher rates of mother-to-child transmission than estimated previously.
- The model of condom use has been simplified, based on a synthesis of national survey data, and previous assumptions about 'disinhibition' no longer apply.
- The model distinguishes ART patients according to whether they are on first-line or second-line ART.
- New data sources included in the model calibration include ARV metabolite data from household surveys (a measure of ART coverage), data on the proportion of child deaths with an HIV diagnosis and data on the age distribution of children on ART [7].
- The model has been updated to better reflect the uncertainty due to missing viral load measurements in ART patients [8].
- The model allows for migrants into a province to have a different HIV profile from current residents in the province.

- The model allows for provincial differences in male rates of contact with sex workers and average breastfeeding durations by HIV-negative/undiagnosed positive mothers.

Thembisa version 4.4 (March 2021)

This is a 'lite' update to Thembisa version 4.3, intended mainly to reflect new programme data. The most significant changes are:

- The model of antenatal bias (the difference between prevalence in pregnant women and women in the general population) has been revised so that the sources of bias are modelled more explicitly, and we no longer assume that the bias is constant over time and across age groups. This affects estimates of HIV incidence trends [9].
- The model of ART initiation has been simplified so that the rate of ART initiation in the first month after diagnosis is a constant multiple of the rate of ART initiation at longer durations after HIV diagnosis, and the effects of sex and CD4 count on these rates of ART initiation are the same at all durations after diagnosis.
- Provincial models are calibrated to recorded death statistics (previously only the national version of the model was calibrated to recorded death data).

It is important to note that version 4.4 does not reflect the demographic impact of the COVID-19 epidemic. In addition, we have not released an Excel version of the Thembisa 4.4 model, as version 4.4 is only a 'lite' update to version 4.3.

References

1. Johnson L. THEMBISA version 1.0: A model for evaluating the impact of HIV/AIDS in South Africa. Centre for Infectious Disease Epidemiology and Research, University of Cape Town; 2014. Available: <http://www.thembisa.org/content/downloadPage/WPversion1>. Accessed 21 April 2016
2. Johnson LF, Chiu C, Myer L, Davies MA, Dorrington RE, Bekker LG, *et al.* Prospects for HIV control in South Africa: a model-based analysis. *Glob Health Action* 2016; **9**:30314.
3. Johnson LF, Rehle TM, Jooste S, Bekker LG. Rates of HIV testing and diagnosis in South Africa, 2002-2012: successes and challenges. *AIDS* 2015; **29**:1401-1409.
4. Johnson LF, Dorrington RE, Moolla H. Progress towards the 2020 targets for HIV diagnosis and antiretroviral treatment in South Africa. *South Afr J HIV Med* 2017; **18**:a694.
5. Johnson LF, Dorrington RE, Moolla H. HIV epidemic drivers in South Africa: a model-based evaluation of factors accounting for inter-provincial differences in HIV prevalence and incidence trends. *South Afr J HIV Med* 2017; **18**:a695.
6. Johnson LF, May MT, Dorrington RE, Cornell M, Boulle A, Egger M, *et al.* Estimating the impact of antiretroviral treatment on adult mortality trends in South Africa: a mathematical modelling study. *PLoS Med* 2017; **14**:e1002468.
7. Johnson LF, Patrick M, Stephen C, Patten G, Dorrington RE, Maskew M, *et al.* Steep declines in pediatric AIDS mortality in South Africa, despite poor progress towards pediatric diagnosis and treatment targets. *Pediatr Infect Dis J* 2020; **39**:843-848.
8. Pillay T, Cornell M, Fox MP, Euvsard J, Fatti G, Technau K, *et al.* Recording of HIV viral loads and viral suppression in South African patients receiving antiretroviral treatment: a multicentre cohort study. *Antivir Ther* 2020; [In press].

9. Johnson LF, Kujawa M, Eaton JW. Challenges in estimating HIV prevalence trends and geographical variation in HIV prevalence using antenatal data: insights from mathematical modelling. *PLoS One* 2020; **15**:e0242595.